These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34300343)

  • 41. Safety and effectiveness of growth hormone therapy in infants with Prader-Willi syndrome younger than 2 years: a prospective study.
    Corripio R; Tubau C; Calvo L; Brun C; Capdevila N; Larramona H; Gabau E
    J Pediatr Endocrinol Metab; 2019 Aug; 32(8):879-884. PubMed ID: 31271556
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors and growth consequences of central hypothyroidism in pediatric patients receiving recombinant human growth hormone.
    Wong K; Levitsky LL; Misra M
    J Pediatr Endocrinol Metab; 2010 May; 23(5):451-61. PubMed ID: 20662344
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fat-Free Mass Is Better Related to Serum Uric Acid Than Metabolic Homeostasis in Prader-Willi Syndrome.
    Marzullo P; Mele C; Minocci A; Mai S; Scacchi M; Sartorio A; Aimaretti G; Grugni G
    Nutrients; 2020 Aug; 12(9):. PubMed ID: 32854398
    [No Abstract]   [Full Text] [Related]  

  • 44. The impact of growth hormone/insulin-like growth factor-I axis and nocturnal breathing disorders on cardiovascular features of adult patients with Prader-Willi syndrome.
    Marzullo P; Marcassa C; Campini R; Eleuteri E; Minocci A; Priano L; Temporelli P; Sartorio A; Vettor R; Liuzzi A; Grugni G
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5639-46. PubMed ID: 16030173
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of growth hormone treatment on children with idiopathic short stature (ISS), idiopathic growth hormone deficiency (IGHD), small for gestational age (SGA) and Turner syndrome (TS) in a tertiary care center.
    Al Shaikh A; Daftardar H; Alghamdi AA; Jamjoom M; Awidah S; Ahmed ME; Soliman AT
    Acta Biomed; 2020 Mar; 91(1):29-40. PubMed ID: 32191651
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thyroid hormone levels in children with Prader-Willi syndrome before and during growth hormone treatment.
    Festen DA; Visser TJ; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):449-56. PubMed ID: 17716335
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Two years of replacement therapy in adults with growth hormone deficiency.
    Verhelst J; Abs R; Vandeweghe M; Mockel J; Legros JJ; Copinschi G; Mahler C; Velkeniers B; Vanhaelst L; Van Aelst A; De Rijdt D; Stevenaert A; Beckers A
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):485-94. PubMed ID: 9404448
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolic health profile in young adults with Prader-Willi syndrome: results of a 2-year randomized, placebo-controlled, crossover GH trial.
    Kuppens RJ; Bakker NE; Siemensma EP; Donze SH; Stijnen T; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2017 Feb; 86(2):297-304. PubMed ID: 27689944
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Growth hormone treatment improves body composition in adults with Prader-Willi syndrome.
    Höybye C; Hilding A; Jacobsson H; Thorén M
    Clin Endocrinol (Oxf); 2003 May; 58(5):653-61. PubMed ID: 12699450
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is there growth hormone deficiency in prader-willi Syndrome? Six arguments to support the presence of hypothalamic growth hormone deficiency in Prader-Willi syndrome.
    Eiholzer U; Bachmann S; l'Allemand D
    Horm Res; 2000; 53 Suppl 3():44-52. PubMed ID: 10971104
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial.
    Donze SH; Kuppens RJ; Bakker NE; van Alfen-van der Velden JAEM; Hokken-Koelega ACS
    Clin Endocrinol (Oxf); 2018 Jun; 88(6):806-812. PubMed ID: 29418016
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects on growth and metabolism of growth hormone treatment for 3 years in 36 children with Prader-Willi syndrome.
    Colmenares A; Pinto G; Taupin P; Giuseppe A; Odent T; Trivin C; Laborde K; Souberbielle JC; Polak M
    Horm Res Paediatr; 2011 Feb; 75(2):123-30. PubMed ID: 20847547
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful early dietary intervention avoids obesity in patients with Prader-Willi syndrome: a ten-year follow-up.
    Schmidt H; Pozza SB; Bonfig W; Schwarz HP; Dokoupil K
    J Pediatr Endocrinol Metab; 2008 Jul; 21(7):651-5. PubMed ID: 18780599
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database).
    Craig ME; Cowell CT; Larsson P; Zipf WB; Reiter EO; Albertsson Wikland K; Ranke MB; Price DA;
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):178-85. PubMed ID: 16886957
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Growth hormone treatment in Prader-Willi syndrome patients: systematic review and meta-analysis.
    Passone CGB; Franco RR; Ito SS; Trindade E; Polak M; Damiani D; Bernardo WM
    BMJ Paediatr Open; 2020; 4(1):e000630. PubMed ID: 32411831
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Growth hormone treatment of children with Prader-Willi syndrome: effects on glucose and insulin homeostasis. Swedish National Growth Hormone Advisory Group.
    Lindgren AC; Hagenäs L; Ritzén EM
    Horm Res; 1999; 51(4):157-61. PubMed ID: 10474015
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effect of recombinant human growth hormone on glucose metabolism in children with growth hormone deficiency].
    Liang L; Zou CC; Li Y; Wang CL; Jiang YJ; Dong GP; Fu JF; Wang XM
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):657-61. PubMed ID: 17217656
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The GHRH + arginine stimulated pituitary GH secretion in children and adults with Prader-Willi syndrome shows age- and BMI-dependent and genotype-related differences.
    Marostica E; Grugni G; De Nicolao G; Marazzi N; Crinò A; Cappa M; Sartorio A
    Growth Horm IGF Res; 2013 Dec; 23(6):261-6. PubMed ID: 24090687
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Growth hormone prescribing patterns in the UK, 2013-2016.
    Shepherd S; Saraff V; Shaw N; Banerjee I; Patel L
    Arch Dis Child; 2019 Jun; 104(6):583-587. PubMed ID: 30567827
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Growth hormone pharmacogenetics: the interactive effect of a microsatellite in the IGF1 promoter region with the GHR-exon 3 and -202 A/C IGFBP3 variants on treatment outcomes of children with severe GH deficiency.
    Costalonga EF; Antonini SR; Guerra G; Coletta RR; Franca MM; Braz AF; Mendonca BB; Arnhold IJ; Jorge AA
    Pharmacogenomics J; 2012 Oct; 12(5):439-45. PubMed ID: 21468024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.